Cargando…

Immunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults

The vaccine efficacy of standard-dose seasonal inactivated influenza vaccines (S-IIV) can be improved by the use of vaccines with higher antigen content or adjuvants. We conducted a randomized controlled trial in older adults to compare cellular and antibody responses of S-IIV versus enhanced vaccin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Athena P. Y., Cohen, Carolyn A., Leung, Nancy H. L., Fang, Vicky J., Gangappa, Shivaprakash, Sambhara, Suryaprakash, Levine, Min Z., Iuliano, A. Danielle, Perera, Ranawaka A. P. M., Ip, Dennis K. M., Peiris, J. S. Malik, Thompson, Mark G., Cowling, Benjamin J., Valkenburg, Sophie A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886864/ https://www.ncbi.nlm.nih.gov/pubmed/33594050 http://dx.doi.org/10.1038/s41541-021-00289-5

Ejemplares similares

A Bovine Adenoviral Vector-Based H5N1 Influenza -Vaccine Provides Enhanced Immunogenicity and Protection at a Significantly Low Dose
por: Sayedahmed, Ekramy E., et al.
Publicado: (2018)

Cross‐reactive antibody‐dependent cellular cytotoxicity antibodies are increased by recent infection in a household study of influenza transmission
por: Valkenburg, Sophie A, et al.
Publicado: (2019)

Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects
por: Li, Rongcheng, et al.
Publicado: (2008)

AS03- and MF59-Adjuvanted Influenza Vaccines in Children
por: Wilkins, Amanda L., et al.
Publicado: (2017)

Immunogenicity and protective efficacy in dogs of an MF59™-adjuvanted vaccine against recombinant canine/porcine coronavirus
por: Decaro, Nicola, et al.
Publicado: (2011)

Nasal delivery of H5N1 avian influenza vaccine formulated with GenJet™ or in vivo-jetPEI(®) induces enhanced serological, cellular and protective immune responses
por: Cao, Weiping, et al.
Publicado: (2018)

Safety of MF59-Adjuvanted Influenza Vaccination in the Elderly: Results of a Comparative Study of MF59-Adjuvanted Vaccine Versus Nonadjuvanted Influenza Vaccine in Northern Italy
por: Villa, Marco, et al.
Publicado: (2013)

A Dual-Functioning 5ʹ-PPP-NS1shRNA that Activates a RIG-I Antiviral Pathway and Suppresses Influenza NS1
por: Singh, Neetu, et al.
Publicado: (2020)

Nasal delivery of Protollin-adjuvanted H5N1 vaccine induces enhanced systemic as well as mucosal immunity in mice
por: Cao, Weiping, et al.
Publicado: (2017)

Adenovirus vector-based multi-epitope vaccine provides partial protection against H5, H7, and H9 avian influenza viruses
por: Hassan, Ahmed O., et al.
Publicado: (2017)

Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults
por: Tsai, Theodore F
Publicado: (2013)

MF59(®)‐adjuvanted vaccines for seasonal and pandemic influenza prophylaxis
por: Banzhoff, Angelika, et al.
Publicado: (2008)

Age-specific differences in the dynamics of protective immunity to influenza
por: Ranjeva, Sylvia, et al.
Publicado: (2019)

Serum anti-neuraminidase antibody responses in human influenza A(H1N1)pdm09 virus infections
por: Karunarathna, Herath M. T. K., et al.
Publicado: (2019)

Indirect protection from vaccinating children against influenza in households
por: Tsang, Tim K., et al.
Publicado: (2019)

Impact of host genetic polymorphisms on response to inactivated influenza vaccine in children
por: Tsang, Tim K., et al.
Publicado: (2023)

Memory-like innate response to booster vaccination with MF-59 adjuvanted influenza vaccine in children
por: Kazmin, Dmitri, et al.
Publicado: (2023)

Indirect Protection from Vaccinating Children against Influenza A Virus Infection in Households
por: Tsang, Tim K., et al.
Publicado: (2022)

Reconstructing household transmission dynamics to estimate the infectiousness of asymptomatic influenza virus infections
por: Tsang, Tim K., et al.
Publicado: (2023)

Effectiveness, immunogenicity, and safety of influenza vaccines with MF59 adjuvant in healthy people of different age groups: A systematic review and meta-analysis
por: Yang, Jing, et al.
Publicado: (2020)

Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial
por: Chappell, Keith J, et al.
Publicado: (2021)

Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age
por: Poder, Airi, et al.
Publicado: (2023)

Quinazolin-derived myeloperoxidase inhibitor suppresses influenza A virus-induced reactive oxygen species, pro-inflammatory mediators and improves cell survival
por: De La Cruz, Juan A., et al.
Publicado: (2021)

Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120/MF59 in Adults
por: Gray, Glenda E, et al.
Publicado: (2021)

The cytomegalovirus gB/MF59 vaccine candidate induces antibodies against an antigenic domain controlling cell-to-cell spread
por: Gomes, A. C., et al.
Publicado: (2023)

The Effect of Age and Recent Influenza Vaccination History on the Immunogenicity and Efficacy of 2009–10 Seasonal Trivalent Inactivated Influenza Vaccination in Children
por: Ng, Sophia, et al.
Publicado: (2013)

Effect of Repeat Vaccination on Immunogenicity of Quadrivalent Cell-Culture and Recombinant Influenza Vaccines Among Healthcare Personnel Aged 18–64 Years: A Randomized, Open-Label Trial
por: Gaglani, Manjusha, et al.
Publicado: (2022)

Immunogenicity of High-Dose Egg-Based, Recombinant, and Cell Culture–Based Influenza Vaccines Compared With Standard-Dose Egg-Based Influenza Vaccine Among Health Care Personnel Aged 18–65 Years in 2019–2020
por: Naleway, Allison L, et al.
Publicado: (2023)

Reconstructing antibody dynamics to estimate the risk of influenza virus infection
por: Tsang, Tim K., et al.
Publicado: (2022)

Author Correction: Reconstructing antibody dynamics to estimate the risk of influenza virus infection
por: Tsang, Tim K., et al.
Publicado: (2023)

Influenza A/H1N1 MF59 adjuvanted vaccine in pregnant women and adverse perinatal outcomes: multicentre study
por: Rubinstein, F, et al.
Publicado: (2013)

Incidence of influenza A(H3N2) virus infections in Hong Kong in a longitudinal sero-epidemiological study, 2009-2015
por: Wei, Vivian W. I., et al.
Publicado: (2018)

The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination
por: Goll, Johannes B., et al.
Publicado: (2022)

The 3′ Untranslated Regions of Influenza Genomic Sequences Are 5′PPP-Independent Ligands for RIG-I
por: Davis, William G., et al.
Publicado: (2012)

Variation by lineage in serum antibody responses to influenza B virus infections
por: Lau, Yiu Chung, et al.
Publicado: (2020)

Influenza virus exploits tunneling nanotubes for cell-to-cell spread
por: Kumar, Amrita, et al.
Publicado: (2017)

Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein
por: Hosseinipour, Mina C, et al.
Publicado: (2020)

Influenza Virus Infects and Depletes Activated Adaptive Immune Responders
por: Bohannon, Caitlin D., et al.
Publicado: (2021)

Safety and Immunogenicity of MF59-Adjuvanted Cell Culture–Derived A/H5N1 Subunit Influenza Virus Vaccine: Dose-Finding Clinical Trials in Adults and the Elderly
por: Frey, Sharon E, et al.
Publicado: (2019)

Vaccine adjuvant MF59 promotes the intranodal differentiation of antigen-loaded and activated monocyte-derived dendritic cells
por: Cioncada, Rossella, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_prsvdfi3e93va7ph5b7cv40h83